{"id":16164,"date":"2026-04-21T00:00:00","date_gmt":"2026-04-21T00:00:00","guid":{"rendered":"https:\/\/www.annualreviews.org\/content\/journals\/10.1146\/annurev-genom-022024-011307?TRACK=RSS"},"modified":"2026-04-21T00:00:00","modified_gmt":"2026-04-21T00:00:00","slug":"cryptic-splicing-in-als-from-driving-disease-progression-to-unlocking-novel-therapeutics","status":"publish","type":"post","link":"https:\/\/sebigec.es\/blog\/index.php\/2026\/04\/21\/cryptic-splicing-in-als-from-driving-disease-progression-to-unlocking-novel-therapeutics\/","title":{"rendered":"Cryptic Splicing in ALS: From Driving Disease Progression to Unlocking Novel Therapeutics"},"content":{"rendered":"<div><p>TDP-43 is an RNA-binding protein that regulates multiple aspects of RNA processing, and its mislocalization from the nucleus to the cytoplasm is a defining feature of amyotrophic lateral sclerosis (ALS). While both loss- and gain-of-function mechanisms contribute to disease, the discovery of cryptic splicing has shed light on the downstream consequences of TDP-43 nuclear clearance for neuronal health. Here, we highlight how loss of nuclear TDP-43 can drive a cascade of events that lead to the impairment of cellular proteostasis and result in a positive feedback loop that perpetuates neuronal dysfunction. This sustains the appearance of cryptic splicing events in genes that are involved in key pathways for the maintenance of axonal homeostasis and synaptic transmission. In contrast to their detrimental effects on neuronal health, cryptic splicing mechanisms may be harnessed to develop novel therapeutic strategies, unprecedentedly expanding the availability of therapeutic avenues for TDP-43 proteinopathies.<\/p><\/div>","protected":false},"excerpt":{"rendered":"<p>TDP-43 is an RNA-binding protein that regulates multiple aspects of RNA processing, and its mislocalization from the nucleus to the cytoplasm is a defining feature of amyotrophic lateral sclerosis (ALS). While both loss- and gain-of-function mechanisms&#8230;<\/p>\n","protected":false},"author":559,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[40,6],"tags":[87],"class_list":["post-16164","post","type-post","status-publish","format-standard","hentry","category-annual-review-of-genomics-and-human-genetics","category-articulos","tag-annurevgenomicshumgenet"],"_links":{"self":[{"href":"https:\/\/sebigec.es\/blog\/index.php\/wp-json\/wp\/v2\/posts\/16164","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sebigec.es\/blog\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sebigec.es\/blog\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sebigec.es\/blog\/index.php\/wp-json\/wp\/v2\/users\/559"}],"replies":[{"embeddable":true,"href":"https:\/\/sebigec.es\/blog\/index.php\/wp-json\/wp\/v2\/comments?post=16164"}],"version-history":[{"count":1,"href":"https:\/\/sebigec.es\/blog\/index.php\/wp-json\/wp\/v2\/posts\/16164\/revisions"}],"predecessor-version":[{"id":16165,"href":"https:\/\/sebigec.es\/blog\/index.php\/wp-json\/wp\/v2\/posts\/16164\/revisions\/16165"}],"wp:attachment":[{"href":"https:\/\/sebigec.es\/blog\/index.php\/wp-json\/wp\/v2\/media?parent=16164"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sebigec.es\/blog\/index.php\/wp-json\/wp\/v2\/categories?post=16164"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sebigec.es\/blog\/index.php\/wp-json\/wp\/v2\/tags?post=16164"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}